GlassScriptPhysician profile
Daniel R Stephenson
NPI 1245454826
$3,270.43
in general payments reported to CMS, 2019-2025
15 companies · $14.90 in 2025
The $14.90 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $826 · 2021: $367 · 2022: $494 · 2023: $1,058 · 2024: $43.37 · 2025: $14.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $805 · Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $805.43 |
| Food and Beverage | $311.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $990.65 | 2019-2023 | Mako, Allograft, Triathlon |
| Saxum Surgical, INC. | $776.81 | 2023 | |
| Micromed INC | $675.65 | 2020 | |
| Smith+Nephew, INC. | $229.09 | 2019-2022 | |
| Depuy Synthes Sales INC. | $203.94 | 2019-2021 | |
| Arthrex, INC. | $180.40 | 2023 | |
| Axogen | $53.89 | 2019 | |
| Vericel Corporation | $29.02 | 2019-2025 | Maci |
| Zimmer Biomet Holdings, INC. | $28.74 | 2019 | |
| Gilead Sciences, INC. | $21.76 | 2024 | |
| Linvatec Corporation | $21.61 | 2024 | Linvatec Shoulder Arthroscopy, Allograft Tissue, Biobrace 23mm |
| Integra Lifesciences Corporation | $16.50 | 2021 | |
| Ermi LLC | $16.07 | 2019 | |
| Horizon Therapeutics Plc | $13.74 | 2019 | |
| Ethicon US, LLC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.